Dose escalation trial designs based on a molecularly targeted endpoint
- 20 May 2005
- journal article
- research article
- Published by Wiley in Statistics in Medicine
- Vol. 24 (14), 2171-2181
- https://doi.org/10.1002/sim.2102
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Adaptive Decision Making in a Lymphocyte Infusion TrialBiometrics, 2002
- Dose-Finding Designs for HIV StudiesBiometrics, 2001
- Dose-Finding Based on Feasibility and Toxicity in T-cell Infusion TrialsBiometrics, 2001
- Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trialsBiostatistics, 2001
- Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed?Journal of Clinical Oncology, 2001
- Development of Target-Based Antineoplastic AgentsInvestigational New Drugs, 2000
- Anticancer Agents Targeting Signaling Molecules and Cancer Cell Environment: Challenges for Drug Development?JNCI Journal of the National Cancer Institute, 1999
- Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.Journal of Clinical Oncology, 1998
- A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical TrialsBiometrics, 1998
- Accelerated Titration Designs for Phase I Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1997